Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart M Cobbe

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Circulation|November 9, 2005
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Chris J Packard, Ian Ford, Michele Robertson, et al.
Lancet (London, England)|November 30, 2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialJames Shepherd, Gerard J Blauw, Michael B Murphy, et al.
Circulation|February 7, 2007
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Naveed Sattar, Heather M Murray, Alex McConnachie, et al.
Journal of the American Geriatrics Society|November 6, 2007
Association between apolipoprotein E4 and cognitive decline in elderly adultsChris J Packard, Rudi G J Westendorp, David J Stott, et al.
The New England Journal of Medicine|April 1, 2009
Rosuvastatin and cardiovascular events in patients undergoing hemodialysisBengt C Fellström, Alan G Jardine, Roland E Schmieder, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Circulation|November 9, 2005
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Chris J Packard, Ian Ford, Michele Robertson, et al.
Lancet (London, England)|November 30, 2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialJames Shepherd, Gerard J Blauw, Michael B Murphy, et al.
Circulation|February 7, 2007
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Naveed Sattar, Heather M Murray, Alex McConnachie, et al.
Journal of the American Geriatrics Society|November 6, 2007
Association between apolipoprotein E4 and cognitive decline in elderly adultsChris J Packard, Rudi G J Westendorp, David J Stott, et al.
The New England Journal of Medicine|April 1, 2009
Rosuvastatin and cardiovascular events in patients undergoing hemodialysisBengt C Fellström, Alan G Jardine, Roland E Schmieder, et al.
Pageof 6